MX2012003329A - Metodo para identificar si un paciente respondera o no a la inmunoterapia. - Google Patents

Metodo para identificar si un paciente respondera o no a la inmunoterapia.

Info

Publication number
MX2012003329A
MX2012003329A MX2012003329A MX2012003329A MX2012003329A MX 2012003329 A MX2012003329 A MX 2012003329A MX 2012003329 A MX2012003329 A MX 2012003329A MX 2012003329 A MX2012003329 A MX 2012003329A MX 2012003329 A MX2012003329 A MX 2012003329A
Authority
MX
Mexico
Prior art keywords
gene expression
methods
responder
immunotherapy
patient
Prior art date
Application number
MX2012003329A
Other languages
English (en)
Inventor
Vincent Brichard
Olivier Gruselle
Jamila Louahed
Benjamin Georges Elie Lea Ghislain Dizier
Fernando Ulloa-Montoya
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2012003329A publication Critical patent/MX2012003329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan métodos para la caracterización de los pacientes como respondentes o no respondentes a la terapia basándose en la expresión diferencial de uno o más genes. También se proporcionan perfiles de expresión genética, microarreglos que comprenden secuencias de ácidos nucleicos que representan los perfiles de expresión genética, y nuevos kits de diagnóstico y métodos para el tratamiento. Los kits y métodos se relacionan con el tratamiento de poblaciones específicas, por ejemplo, de los pacientes de cáncer, como se caractericen por su perfil de expresión genética, que padezcan de tumores que expresen MAGE.
MX2012003329A 2009-09-18 2010-09-17 Metodo para identificar si un paciente respondera o no a la inmunoterapia. MX2012003329A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22704609P 2009-09-18 2009-09-18
US27838709P 2009-10-06 2009-10-06
GBGB0917457.4A GB0917457D0 (en) 2009-10-06 2009-10-06 Method
PCT/EP2010/063751 WO2011033095A1 (en) 2009-09-18 2010-09-17 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (1)

Publication Number Publication Date
MX2012003329A true MX2012003329A (es) 2012-04-20

Family

ID=41393894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003329A MX2012003329A (es) 2009-09-18 2010-09-17 Metodo para identificar si un paciente respondera o no a la inmunoterapia.

Country Status (14)

Country Link
US (1) US20110070268A1 (es)
EP (1) EP2478116A1 (es)
JP (1) JP2013505008A (es)
KR (1) KR20130055553A (es)
CN (1) CN102597269A (es)
AU (1) AU2010297248A1 (es)
BR (1) BR112012006088A2 (es)
CA (1) CA2773666A1 (es)
EA (1) EA201290107A1 (es)
GB (1) GB0917457D0 (es)
IL (1) IL218313A0 (es)
MX (1) MX2012003329A (es)
SG (1) SG179129A1 (es)
WO (1) WO2011033095A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043580A1 (en) 2013-03-15 2022-08-17 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
AU2015284460B2 (en) 2014-07-02 2021-10-07 Myriad Mypath, Llc Genes and gene signatures for diagnosis and treatment of melanoma
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
WO2017193080A1 (en) * 2016-05-05 2017-11-09 Nantomics, Llc Checkpoint failure and methods therefor
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
EP4161658A1 (en) * 2020-06-01 2023-04-12 Dana-Farber Cancer Institute, Inc. Methods for modulating mhc-i expression and immunotherapy uses thereof
CN115495026B (zh) * 2022-11-21 2023-03-10 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MXPA01007721A (es) 1999-01-29 2003-07-14 Corixa Corp Proteinas de fusion her-2/neu.
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
HUP0500539A2 (en) 2002-02-04 2006-09-28 Corixa Corp New immunoeffector 2-deoxi-2-amino-3-d glucopyranose derivatives
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
CN100360558C (zh) 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
CA2516182A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
JP2007516692A (ja) * 2003-03-07 2007-06-28 アビアラデックス，インコーポレイティド 乳癌の徴候
WO2004081564A1 (en) 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2348110B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
PL1668152T3 (pl) * 2003-08-28 2009-06-30 Ipsogen Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka
CA2540894A1 (en) 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
US8187805B2 (en) * 2004-02-09 2012-05-29 Fuso Pharmaceutical Industries, Ltd. Method of detecting nucleic acid and utilization thereof
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
WO2005108610A2 (en) * 2004-04-05 2005-11-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for the selection of subjects for multiple sclerosis therapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
MX2007006441A (es) * 2004-11-30 2007-08-14 Johnson & Johnson Prognosis de cancer de pulmon.
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
US20080193938A1 (en) 2005-04-01 2008-08-14 Yu Kun Materials And Methods Relating To Breast Cancer Classification
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
JP5171812B2 (ja) * 2006-04-27 2013-03-27 ユニベルシテ ドゥ モントリオール 移植片対宿主病のリスクの評価および低減
EP2390356A1 (en) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FASLG gene
CN101821629A (zh) * 2007-09-10 2010-09-01 诺瓦提斯研究基金会弗里德里克·米谢尔生物医学研究所 用于预测患有肝脏病毒性感染的受试者针对抗病毒疗法的应答的方法
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy

Also Published As

Publication number Publication date
WO2011033095A1 (en) 2011-03-24
CN102597269A (zh) 2012-07-18
BR112012006088A2 (pt) 2020-08-11
EA201290107A1 (ru) 2012-10-30
KR20130055553A (ko) 2013-05-28
EP2478116A1 (en) 2012-07-25
AU2010297248A1 (en) 2012-04-12
CA2773666A1 (en) 2011-03-24
IL218313A0 (en) 2012-04-30
US20110070268A1 (en) 2011-03-24
GB0917457D0 (en) 2009-11-18
SG179129A1 (en) 2012-05-30
JP2013505008A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2012174256A3 (en) Dna methylation profiles in cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2012068383A3 (en) ncRNA AND USES THEREOF
UA110790C2 (uk) Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
IN2012DN04944A (es)
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
WO2012093821A3 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
MX344543B (es) Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal